A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of E6201 in Subjects With Advanced Solid Tumors

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2008
The purpose of this study is to determine the maximum tolerated dose (MTD), safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary anti-tumor activity of E6201 in subjects with advanced solid tumors.
Epistemonikos ID: fc18e71dd85cc9049ac9e68ceab361478e001d44
First added on: May 05, 2024